ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt
ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt Source link Avisol Capital Partners
ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt Read More »
Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease (CGEM)
Pgiam/iStock via Getty Images I covered Cullinan Therapeutics, Inc. (NASDAQ:CGEM) twice in the last year, and both times I wondered why the stock was trading below cash. It had a decent enough market cap for a small biotech; it just
Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease (CGEM) Read More »